← 홈

HER2+ 유방암

60개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-14 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 60개
ADCSFDAFDABiologicFundación Pública Andaluza para…Deruxtecan-Dlnk Quantificat…Phase 3

Datopotamab deruxtecan (Datopotamab deruxtecan)

Breast Cancer; Metastatic Breast Cancer · Lung Cancer

#LungCancer#ADC#Phase3#FDA승인#항체약물접합체+5
효능 ORR 79%임상시험 44상태 RECRUITING
ADCSFDAFDABiologicstaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Fam-Trastuzumab Deruxtecan-Nxki)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#FDA승인#항체약물접합체+4
효능 ORR 71.7%임상시험 23상태 RECRUITING
ADCSHotBiologicRocheDM1 via butelase-1 with ABD…Approved

trastuzumab (Herceptin, Trastuzumab Emtansine)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · Metastatic Salivary Gland Carcinoma

#MetastaticSalivaryGlandCarcinoma#ADC#Approved#인기#항체약물접합체+5
효능 ORR 69.7%임상시험 106상태 RECRUITING
ADCBBiologicGileadaxisPhase 3

sacituzumab govitecan (Trodelvy)

Breast Cancer; Metastatic Breast Cancer · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 44%임상시험 87상태 RECRUITING
ADCBBiologicMerck Sharp & Dohme LLCPhase 2

Cytoxan (Cytoxan)

Multiple Myeloma, Refractory · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 95%임상시험 73상태 RECRUITING
ADCBiologicSpanish Breast Cancer Research …sPhase 2

Taxotere (Taxotere)

Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 88.1%임상시험 68상태 RECRUITING
ADCBiologicHoffmann-La RochePhase 2

Xeloda (Xeloda)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#인기#항체약물접합체+2
효능 ORR 30%임상시험 65상태 RECRUITING
ADCBiologicHoffmann-La RochePhase 2

Empagliflozin (Empagliflozin)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#인기#항체약물접합체+2
임상시험 61상태 RECRUITING
ADCBiologicPfizerderuxtecan and tucatinibPhase 3

Tucatinib (Tucatinib)

Dynamic Tumor Resistance; Metastatic Colorectal Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 100%임상시험 57상태 RECRUITING
ADCBiologicRochesPhase 1

trastuzumab (Herceptin, trastuzumab-MCC-DM1)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase1#인기#항체약물접합체+3
효능 ORR 69.7%임상시험 56상태 ACTIVE
ADCBiologicJiangsu HengRui Medicine Co., L…Phase 2

Famitinib (Famitinib)

Advanced Breast Cancer; Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+5
임상시험 53상태 RECRUITING
ADCBiologicAstraZenecaderuxtecan or sacituzumab g…Phase 2

Capivasertib (Capivasertib)

Metastatic Breast Cancer · FRα

#FR#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 56.5%임상시험 50상태 RECRUITING
ADCBiologicstaleGBG Forschungs GmbHPhase 2

Inavolisib (Inavolisib)

HER2-positive Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 11.5%임상시험 31상태 RECRUITING
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Pertuzumab + trastuzumab)

Elderly Metastatic Breast Cancer Population · Elderly Metastatic Breast Cancer Populat

#ElderlyMetastaticBreastCancerPop#Antibody#Phase2#항체#면역항체+2
효능 ORR 69.3%임상시험 31상태 ACTIVE
ADCBiologicstaleInstitut Claudius RegaudApproved

Pharmacokinetics blood samples (Pharmacokinetics blood samples)

Locally Advanced or Metastatic Breast Cancers · Locally Advanced or Metastatic Breast Ca

#LocallyAdvancedorMetastaticBreas#ADC#Approved#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 91.2%임상시험 31상태 RECRUITING
ADCBiologicstaleChipscreen Biosciences, Ltd.Phase 3

taxane drug (taxane drug)

HER2-positive Metastatic Breast Cancer; First-line Treatment · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 81.1%임상시험 31상태 RECRUITING
ADCBiologicstaleJiangsu HengRui Medicine Co., L…Phase 2

pyrotinib plus capecitabine (pyrotinib plus capecitabine)

Metastatic Breast Cancer in the Brain · Metastatic Breast Cancer in the Brain

#MetastaticBreastCancerintheBrain#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 30상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 3

Patritumab Deruxtecan (Patritumab Deruxtecan)

Lung Neoplasm Malignant · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 28상태 RECRUITING
AntibodystaleZhiyong YuPhase 2

Inetetamab (Inetetamab)

Metastatic Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+3
임상시험 26상태 ACTIVE
ADCBiologicstaleShanghai Hengrui Pharmaceutical…Phase 2

SHR-A2102 (SHR-A2102)

Advanced Breast Cancer; Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 25상태 RECRUITING

1 / 3 페이지

← 이전다음 →